
TY  - JOUR
TI  - American College of Clinical Pharmacy: Third Annual Winter Practice and Research Forum February 7–10, 1993 Marina Marriott Ft. Lauderdale, Florida
JO  - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
VL  - 12
IS  - 6
SN  - 0277-0008
UR  - https://doi.org/10.1002/j.1875-9114.1992.tb04496.x
DO  - doi:10.1002/j.1875-9114.1992.tb04496.x
SP  - 496
EP  - 508
PY  - 1992
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - European Journal of Heart Failure
JA  - Eur J Heart Fail
VL  - 20
IS  - S1
SN  - 1388-9842
UR  - https://doi.org/10.1002/ejhf.1197
DO  - doi:10.1002/ejhf.1197
SP  - 5
EP  - 638
PY  - 2018
ER  - 

TY  - JOUR
TI  - Abstract
JO  - Pharmacoepidemiology and Drug Safety
JA  - Pharmacoepidemiol Drug Saf
VL  - 26
IS  - S2
SN  - 1053-8569
UR  - https://doi.org/10.1002/pds.4275
DO  - doi:10.1002/pds.4275
SP  - 3
EP  - 636
PY  - 2017
ER  - 

TY  - JOUR
TI  - RESEARCH COMMUNICATIONS OF THE 28th ECVIM-CA CONGRESS
JO  - Journal of Veterinary Internal Medicine
JA  - J Vet Intern Med
VL  - 33
IS  - 2
SN  - 0891-6640
UR  - https://doi.org/10.1111/jvim.15372
DO  - doi:10.1111/jvim.15372
SP  - 1015
EP  - 1101
PY  - 2019
ER  - 

AU  - Morgan, B. Paul
TI  - Complement
SN  - 9780470686386
UR  - https://doi.org/10.1002/9780470688618.taw0090
DO  - doi:10.1002/9780470688618.taw0090
KW  - complement (C), component of innate immunity and pathogen defense
KW  - C system component proteins
KW  - constituent pathways of C system and component proteins in sequential order
KW  - classical pathway activation
KW  - alternative pathway activation efficiency and low-level or ‘tickover’ activation
KW  - membrane attack pathway
KW  - role of C in apoptosis
KW  - complement therapies, manipulating C system therapeutically in diseases
PY  - 2019
AB  - Abstract
ER  - 

AU  - Langleben, Daniel D.
AU  - Willard, Dan F. X.
AU  - Moriarty, Jane C.
C7  - pp. 215-236
TI  - Brain Imaging of Deception
SN  - 9780470976999
UR  - https://doi.org/10.1002/9781119968900.ch13
DO  - doi:10.1002/9781119968900.ch13
SP  - 215-236
KW  - Comparison Question Test
KW  - Concealed Information Test
KW  - deception
KW  - functional magnetic resonance imaging
KW  - Guilty Knowledge Test
KW  - lie detection
PY  - 2019
AB  - Summary Determining truth is an essential part of many human interactions and endeavors. Unfortunately, lying and deception are common in society, and generally difficult to identify. A scientific, objective means of distinguishing truth from lies would have profound implications for the legal system as well as for society as a whole. The traditional polygraph is fraught with problems, and is typically excluded from court proceedings. In the last decade, researchers have developed functional magnetic resonance imaging techniques that suggest the possibility of accurately identifying the neural activation patterns associated with lying. However, at present many questions about the feasibility of these techniques for real-world use remain, and it would be premature to allow their use in court.
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Pediatric Transplantation
JA  - Pediatr Transplantation
VL  - 17
IS  - s1
SN  - 9780470976999
UR  - https://doi.org/10.1111/petr.12122
DO  - doi:10.1111/petr.12122
SP  - 1
EP  - 118
PY  - 2013
ER  - 

TY  - JOUR
TI  - ABSTRACTS: Pediatric & Adult Interventional Cardiac Symposium (PICS/AICS 2013)
JO  - Catheterization and Cardiovascular Interventions
JA  - Cathet. Cardiovasc. Intervent.
VL  - 81
IS  - 1
SN  - 9780470976999
UR  - https://doi.org/10.1002/ccd.24762
DO  - doi:10.1002/ccd.24762
SP  - 174
EP  - 221
PY  - 2013
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - British Journal of Haematology
JA  - Br J Haematol
VL  - 181
IS  - S1
SN  - 9780470976999
UR  - https://doi.org/10.1111/bjh.15226
DO  - doi:10.1111/bjh.15226
SP  - 5
EP  - 211
PY  - 2018
ER  - 

TY  - JOUR
AU  - Hohnloser, Stefan H.
AU  - Camm, John
AU  - Cappato, Riccardo
AU  - Diener, Hans-Christoph
AU  - Heidbuchel, Hein
AU  - Lanz, Hans-Joachim
AU  - Mont, Lluís
AU  - Morillo, Carlos A.
AU  - Smolnik, Rüdiger
AU  - Yin, Ophelia Q.P.
AU  - Kautzner, Josef
C8  - CLC-17-0880.R1
TI  - Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
JO  - Clinical Cardiology
JA  - Clin Cardiol
VL  - 41
IS  - 4
SN  - 9780470976999
UR  - https://doi.org/10.1002/clc.22918
DO  - doi:10.1002/clc.22918
SP  - 440
EP  - 449
KW  - Atrial Fibrillation
KW  - Catheter Ablation
KW  - Direct Oral Anticoagulant
KW  - Direct Oral Anticoagulant Edoxaban
KW  - Non–Vitamin K Oral Anticoagulants
KW  - Periprocedural
PY  - 2018
AB  - Patients with atrial fibrillation (AF) are at an approximately 0.5% to 3% increased risk of thromboembolism during and immediately after catheter ablation. Treatment guidelines recommend periprocedural oral anticoagulation plus unfractionated heparin during ablation. Rivaroxaban and dabigatran are the only non?vitamin K oral anticoagulants for which there are randomized controlled trials assessing uninterrupted anticoagulation in patients undergoing catheter ablation of AF. Edoxaban, a direct factor Xa inhibitor, is noninferior vs warfarin for the prevention of stroke or systemic embolism with less major bleeding in patients with nonvalvular AF. The ELIMINATE-AF (Evaluation of Edoxaban Compared With VKA in Subjects Undergoing Catheter Ablation of Nonvalvular Atrial Fibrillation) trial is a multinational, multicenter, prospective, randomized, open-label, parallel-group, blinded-endpoint evaluation (PROBE) study to assess the safety and efficacy of once-daily edoxaban 60?mg (30?mg in patients indicated for a dose reduction) vs vitamin K antagonists (VKA) in patients with nonvalvular AF undergoing catheter ablation (http://www.ClinicalTrials.gov: NCT02942576). A total of 560 patients are planned for randomization to edoxaban or VKA (2:1 ratio) to obtain 450 patients fully compliant with the protocol. Patients will complete 21 to 28?days of anticoagulation prior to the ablation and a 90-day post-ablation period. The primary efficacy endpoint is the composite of all-cause death, stroke, and major bleeding. The primary safety endpoint is major bleeding. A magnetic resonance imaging substudy will assess the incidence of silent cerebral lesions post-ablation. ELIMINATE-AF will define the efficacy and safety of edoxaban for uninterrupted oral anticoagulation during catheter ablation of AF.
ER  - 

TY  - JOUR
TI  - Abstracts-Posters
JO  - Alcoholism: Clinical and Experimental Research
JA  - Alcohol Clin Exp Res
VL  - 42
IS  - S1
SN  - 9780470976999
UR  - https://doi.org/10.1111/acer.13747
DO  - doi:10.1111/acer.13747
SP  - 19A
EP  - 270A
PY  - 2018
ER  - 

TY  - JOUR
TI  - Swiss Society of Surgery
JO  - BJS (British Journal of Surgery)
JA  - Br J Surg
VL  - 103
IS  - S4
SN  - 9780470976999
UR  - https://doi.org/10.1002/bjs.10214
DO  - doi:10.1002/bjs.10214
SP  - 5
EP  - 28
PY  - 2016
ER  - 

TY  - JOUR
TI  - Poster Abstracts
JO  - Journal of Paediatrics and Child Health
VL  - 46
IS  - s1
SN  - 9780470976999
UR  - https://doi.org/10.1111/j.1440-1754.2010.01708.x
DO  - doi:10.1111/j.1440-1754.2010.01708.x
SP  - 56
EP  - 96
PY  - 2010
ER  - 

TY  - JOUR
TI  - 58th ANNUAL MEETING AND EXHIBITION
JO  - Medical Physics
JA  - Med. Phys.
VL  - 43
IS  - 6Part47
SN  - 9780470976999
UR  - https://doi.org/10.1002/j.2473-4209.2016.tb00353.x
DO  - doi:10.1002/j.2473-4209.2016.tb00353.x
SP  - 3212
EP  - 3938
PY  - 2016
ER  - 

TY  - JOUR
TI  - American College of Clinical Pharmacy
JO  - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
VL  - 10
IS  - 3
SN  - 9780470976999
UR  - https://doi.org/10.1002/j.1875-9114.1990.tb02580.x
DO  - doi:10.1002/j.1875-9114.1990.tb02580.x
SP  - 231
EP  - 257
PY  - 1990
ER  - 

TY  - JOUR
TI  - Abstract Journal Colorectal Surgery
JO  - ANZ Journal of Surgery
JA  - ANZ Journal of Surgery
VL  - 89
IS  - S1
SN  - 9780470976999
UR  - https://doi.org/10.1111/ans.15184
DO  - doi:10.1111/ans.15184
SP  - 23
EP  - 45
PY  - 2019
ER  - 

TY  - JOUR
TI  - Oral abstracts
JO  - Vox Sanguinis
VL  - 96
IS  - s1
SN  - 9780470976999
UR  - https://doi.org/10.1111/j.1423-0410.2009.01155.x
DO  - doi:10.1111/j.1423-0410.2009.01155.x
SP  - 1
EP  - 62
PY  - 2009
ER  - 

TY  - JOUR
TI  - SIOP 2015 Scientific Programme + Index
JO  - Pediatric Blood & Cancer
JA  - Pediatr Blood Cancer
VL  - 62
IS  - S4
SN  - 9780470976999
UR  - https://doi.org/10.1002/pbc.25715
DO  - doi:10.1002/pbc.25715
SP  - S143
EP  - S418
PY  - 2015
ER  - 

TY  - JOUR
TI  - Scientific
JO  - Transfusion
VL  - 46
IS  - 9s
SN  - 9780470976999
UR  - https://doi.org/10.1111/j.1537-2995.2006.01023_1.x
DO  - doi:10.1111/j.1537-2995.2006.01023_1.x
SP  - 1A
EP  - 164A
PY  - 2006
ER  - 

TY  - JOUR
TI  - Administrative Operations
JO  - Transfusion
VL  - 46
IS  - 9s
SN  - 9780470976999
UR  - https://doi.org/10.1111/j.1537-2995.2006.01023_2.x
DO  - doi:10.1111/j.1537-2995.2006.01023_2.x
SP  - 165A
EP  - 233A
PY  - 2006
ER  - 
